Evaluating the efficacy of N-acetyl cysteine (NAC) in dyspeptic patients and negative Helicobacter pylori infection

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170716035126N3

Enrollment

Registered

2018-02-17

Start date

2018-03-06

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyspepsia. Functional dyspepsia

Interventions

Intervention 1: Intervention group: Patients will receive pantaprazol 40 mg and NAC 600 mg daily. Intervention 2: Control group: Patients will receive only pantaprazol 40 mg daily.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with the complaint of dyspepsia and negative H. pylori test

Exclusion criteria

Exclusion criteria: Chronic use of NSAIDs or corticosteroids fro more than a month Gastric outlet obstruction diagnosed in endoscopy Pregnancy (due to the side effects) Chronic kidney disease GI malignancy previous gastric surgery Patients receiving NAC due to asthma or COPD

Design outcomes

Primary

Measure	Time frame
Dyspepsia symptoms. Timepoint: Before and 8 weeks after intervention. Method of measurement: Using ROME III criteria.;Need for endoscopy. Timepoint: 8 weeks after intervention. Method of measurement: No change or deterioration of dyspepsia symptoms.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Habibzadeh

Ardabil University of Medical Sciences

afshin.habibzadeh@gmail.com+98 45 3352 2391

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026